Malignant Pleural Mesothelioma – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of malignant pleural mesothelioma (MPM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of MPM for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting incident and prevalent patient populations in these markets, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s MPM forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with MPM each year?
- How will improvements in survival change the number of people living with a diagnosis of MPM?
- How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for MPM?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MPM over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following MPM patient populations:
- Diagnosed incident cases.
- Diagnosed incident cases by resection status.
- Diagnosed incident cases of metastatic recurrent disease.
- Diagnosed prevalent cases.
- Unresectable drug-treatable prevalent cases.
- Resectable drug-treatable prevalent cases.
- Resectable non-drug-treatable prevalent cases.
- Diagnosed first-line metastatic drug-treatable population.
Note: Coverage may vary by country.
Table of contents
Jackie Liu, M.P.H., Ph.D., Manager, Epidemiology. She first joined Clarivate as a Medtech analyst and worked on forecasting the global vascular devices market. She received her Ph.D. in molecular genetics and her M.P.H. in epidemiology from the University of Toronto in Canada.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.